OUR PURPOSE Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. OUR CREDENTIALS Kuros is a Swiss-headquartered biotech company, listed on the SIX Swiss Stock Exchange since 2016 (under symbol KURN). With additional operations in the Netherlands and the USA, we continue to grow our global team. To deliver the ideal bone graft, you need the highest quality and quantity of scientific evidence behind it. We believe that this is a key differentiator for Kuros, given the urgent need to advance bone healing. โข Listing on the ๐ฆ๐๐ซ ๐ฆ๐๐ถ๐๐ ๐๐ ๐ฐ๐ต๐ฎ๐ป๐ด๐ฒ under the symbol KURN since 2016 โข A commercial & research footprint that spans >๐ฎ๐ฌ ๐บ๐ฎ๐ฟ๐ธ๐ฒ๐๐ โข Dozens of ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐ฎ๐ป๐ฑ ๐๐ฐ๐ถ๐ฒ๐ป๐๐ถ๐ณ๐ถ๐ฐ ๐ฒ๐ ๐ฝ๐ฒ๐ฟ๐ ๐ฎ๐ฑ๐๐ถ๐๐ฒ๐ฟ๐ โข >๐ฎ๐ฑ orthobiologics-related ๐ฝ๐ฎ๐๐ฒ๐ป๐๐ โข >๐ฐ๐ฌ๐ฌ ๐ฝ๐ฎ๐๐ถ๐ฒ๐ป๐๐ ๐ฒ๐๐ฎ๐น๐๐ฎ๐๐ฒ๐ฑ in Level I, randomized controlled clinical trials โข >๐ฎ๐ฌ well-controlled ๐๐ฒ๐๐ฒ๐น ๐-๐๐ฉ ๐ฐ๐น๐ถ๐ป๐ถ๐ฐ๐ฎ๐น ๐๐ฟ๐ถ๐ฎ๐น๐ ๐ถ๐ป๐ถ๐๐ถ๐ฎ๐๐ฒ๐ฑ, including 6 that are completeยน โข Published Level I evidence published in ๐๐๐๐๐ CONTACT KUROS TO FIND OUT MORE >>>>
New Marketing & PR activity โ 54 fresh signals just appeared.
The order this company entered each market โ oldest to newest
Kuros Biosciences Achieves Profitability Growth
๐๐๐ฟ๐ผ๐ ๐ฎ๐ป๐ป๐ผ๐๐ป๐ฐ๐ฒ๐ฑ ๐๐ผ๐ฑ๐ฎ๐ ๐ฐ๐ฑ% ๐๐ญ ๐ฎ๐ฌ๐ฎ๐ฒ ๐๐ฒ๐ฎ๐ฟ-๐ผ๐๐ฒ๐ฟ-๐๐ฒ๐ฎ๐ฟ ๐๐ฎ๐น๐ฒ๐ ๐ด๐ฟ๐ผ๐๐๐ต ๐ฎ๐ป๐ฑ ๐ถ๐ป๐ฐ๐ฟ๐ฒ๐ฎ๐๐ฒ๐ ๐ผ๐๐ฒ๐ฟ๐ฎ๐น๐น ๐ฝ๐ฟ๐ผ๐ณ๐ถ๐๐ฎ๐ฏ๐ถ๐น๐ถ๐๐ A dozen milestones that mark our next phase of scale โ see whatโs driving the momentum: 1) Total Medical Device sales +45% to USD 92.4M 2) EBITDA increased 46% to USD 7.4M3) Adjusted EBITDA increased 61% to USD 12.5M (13.6% margin) 4) Net profit amounted to USD 4.4M5) Cash on track; funding U.S. and Netherlands expans ...
Sign up to see the full signal feed
How Kuros Biosciences's international expansion compares to its competitors
Kuros BiosciencesYouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Kuros BiosciencesYou | 2 | 0 | +1767% | 59 | 56 |
8 roles opened in the last 90 days. Information Technology-led and concentrated in Netherlands.
Bilthoven, Utrecht, Netherlands ยท 3d ago
Supply Chain Analyst
San Francisco, CA ยท 2w ago
Regional Sales Manager - Northern California
Bilthoven, Utrecht, Netherlands ยท 3w ago
Warehouse and Customer Service Employee
28 technologies detected across the stack.
2 active campaigns across 55 markets.
Ended
Ended3 mentions in the last 90 days.
Swiss medtech firm Kuros Biosciences reported 45% revenue growth to CHF 92.4M and net profit of CHF 4.4M in H1 2026, driven by MagnetOs product line.
Kuros Biosciences opens manufacturing facility in Georgia, receives UBS buy rating. MagnetOs bone substitute drives US growth with Q1 sales up 51% to $43.4M, targeting $330M by 2028.
Kuros Biosciences will showcase MagnetOsโข commercial momentum and scalable quality growth plan at Capital Markets Day in Zรผrich.
Unlock verified emails & direct dials
Free ยท No credit card needed
Quick answers about Kuros Biosciences's business, markets, and growth signals.
โWe reach accounts the week they land in-market โ not the quarter after.โ
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
ยฉ 2026 Pubrio. All rights reserved.
